Skip to Content
MDPIMDPI
Current OncologyCurrent Oncology
PDF
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
  • Editorial
  • Open Access

1 October 2014

Meaningful Patient Representation Informing Canada’s Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review

,
,
,
and
1
Pharmacoeconomics Research Unit, Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; Institute for Health Policy, Management and Evaluation, University of Toronto; and Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada
2
Department of Philosophy, University of Leth-bridge, Lethbridge, AB, Canada
3
Expert Review Committee, Pan-Canadian Oncology Drug Review, Toronto, ON, Canada
4
Department of Psychology, University of Saskatchewan, Saskatoon, SK, Canada
Curr. Oncol.2014, 21(5), 263-266;https://doi.org/10.3747/co.21.2128
Version Notes
Order Reprints

Abstract

In this interview with the patient representatives on the Expert Review Committee (pERC) of the Pan-Canadian Oncology Drug Review (pCODR), those representatives offer their views about how to be a valuable contributing member of Canada’s national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pCODR from the perspective of the patient representatives.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?
Previous
Design and Implementation of a Community-Based Exercise Program for Breast Cancer Patients
Next